Agnelli, G., Buller, H.R., Cohen, A., Curto, M., Gallus, A.S., Johnson, M., Masiukiewicz, U., Pak, R., Thompson, J., Raskob, G.E., et al. (2013). Oral apixaban for the treatment of acute venous thromboembolism. N. Engl. J. Med. 369, 799-808.
Ambrozic, A., Avicin, T., Ichikawa, K., Kveder, T., Matsuura, E., Hojnik, M., Atsumi, T., Rozman, B., and Koike, T. (2002). Anti-beta(2)-glycoprotein I antibodies in children with atopic dermatitis. Int. Immunol. 14, 823-830.
Amengual, O., and Atsumi, T. (2018). Antiphospholipid syndrome, "the best prophet of the future". Mod. Rheumatol. 28, 409-416.
Amengual, O., Atsumi, T., Khamashta, M.A., Koike, T., and Hughes, G.R. (1996). Specificity of ELISA for antibody to beta 2-glycoprotein I in patients with antiphospholipid syndrome. Br. J. Rheumatol. 35, 1239-1243.
Amengual, O., Atsumi, T., and Koike, T. (2003). Specificities, properties, and clinical significance of antiprothrombin antibodies. Arthritis Rheum. 48, 886-895.
Amengual, O., Forastiero, R., Sugiura-Ogasawara, M., Otomo, K., Oku, K., Favas, C., Delgado Alves, J., Zigon, P., Ambrozic, A., Tomsic, M., et al. (2017). Evaluation of phosphatidylserine- dependent antiprothrombin antibody testing for the diagnosis of antiphospholipid syndrome: results of an international multicentre study. Lupus 26, 266-276.
Andreoli, L., and Tincani, A. (2012). Beyond the "syndrome": antiphospholipid antibodies as risk factors. Arthritis Rheum. 64, 342-345.
Arachchillage, D.R., Efthymiou, M., Mackie, I.J., Lawrie, A.S., Machin, S.J., and Cohen, H. (2015). Rivaroxaban and warfarin achieve effective anticoagulation, as assessed by inhibition of TG and in-vivo markers of coagulation activation, in patients with venous thromboembolism. Thromb. Res. 135, 388-393.
Arad, A., Proulle, V., Furie, R.A., Furie, B.C., and Furie, B. (2011). beta(2)-Glycoprotein-1 autoantibodies from patients with antiphospholipid syndrome are sufficient to potentiate arterial thrombus formation in a mouse model. Blood 117, 3453-3459.
Atsumi, T., Amengual, O., Yasuda, S., and Koike, T. (2004). Antiprothrombin antibodies--are they worth assaying? Thromb. Res. 114, 533-538.
Atsumi, T., Ieko, M., Bertolaccini, M.L., Ichikawa, K., Tsutsumi, A., Matsuura, E., and Koike, T. (2000). Association of autoantibodies against the phosphatidylserine-prothrombin complex with manifestations of the antiphospholipid syndrome and with the presence of lupus anticoagulant. Arthritis Rheum. 43, 1982-1993.
Becarevic, M., Stojanovic, L., Ignjatovic, S., and Dopsaj, V. (2016). The IgM isotype of anti- annexin A5 antibodies and multiple positivity of conventional antiphospholipid antibodies: increasing the number of clinical manifestations of primary antiphospholipid syndrome. Clin. Rheumatol. 35, 1361-1365.
Boffa, M.C., Boinot, C., De Carolis, S., Rovere-Querini, P., Aurousseau, M.H., Allegri, F., Nicaise-Roland, P., Barra, A., Botta, A., Ambrozic, A., et al. (2009). Laboratory criteria of the obstetrical antiphospholipid syndrome. Data from a multicentric prospective European women cohort. Thromb. Haemost. 102, 25-28.
Brandt, J.T., Triplett, D.A., Alving, B., and Scharrer, I. (1995). Criteria for the diagnosis of lupus anticoagulants: an update. On behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH. Thromb. Haemost. 74, 1185-1190.
Chayoua, W., Kelchtermans, H., Gris, J.C., Moore, G.W., Musial, J., Wahl, D., de Groot, P.G., de Laat, B., and Devreese, K.M.J. (2020). The (non-)sense of detecting anti-cardiolipin and anti- beta2glycoprotein I IgM antibodies in the antiphospholipid syndrome. J. Thromb. Haemost. 18, 169-179.
Cohen, H., Hunt, B.J., Efthymiou, M., Arachchillage, D.R., Mackie, I.J., Clawson, S., Sylvestre, Y., Machin, S.J., Bertolaccini, M.L., Ruiz-Castellano, M., et al. (2016). Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial. Lancet Haematol. 3, e426-436.
de Groot, P.G., Lutters, B., Derksen, R.H., Lisman, T., Meijers, J.C., and Rosendaal, F.R. (2005). Lupus anticoagulants and the risk of a first episode of deep venous thrombosis. J. Thromb. Haemost. 3, 1993-1997.
De Laat, B., Derksen, R.H., Reber, G., Musial, J., Swadzba, J., Bozic, B., Cucnik, S., Regnault, V., Forastiero, R., Woodhams, B.J., et al. (2011). An international multicentre-laboratory evaluation of a new assay to detect specifically lupus anticoagulants dependent on the presence of anti-beta2-glycoprotein autoantibodies. J. Thromb. Haemost. 9, 149-153.
Del Ross, T., Ruffatti, A., Cuffaro, S., Tonello, M., Calligaro, A., Favaro, M., Facchinetti, M., Hoxha, A., and Punzi, L. (2015). The clinical relevance of the IgM isotype of antiphospholipid antibodies in the vascular antiphospholipid syndrome. Thromb. Res. 136, 883-886.
Edwards, J.C., and Cambridge, G. (2006). B-cell targeting in rheumatoid arthritis and other autoimmune diseases. Nat. Rev. Immunol. 6, 394-403.
Erkan, D., Vega, J., Ramon, G., Kozora, E., and Lockshin, M.D. (2013). A pilot open-label phase II trial of rituximab for non-criteria manifestations of antiphospholipid syndrome. Arthritis Rheum. 65, 464-471.
Finazzi, G., Brancaccio, V., Moia, M., Ciaverella, N., Mazzucconi, M.G., Schinco, P.C., Ruggeri, M., Pogliani, E.M., Gamba, G., Rossi, E., et al. (1996). Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four-year prospective study from the Italian Registry. Am. J. Med. 100, 530-536.
Fujieda, Y., Atsumi, T., Amengual, O., Odani, T., Otomo, K., Kato, M., Oku, K., Kon, Y., Horita, T., Yasuda, S., et al. (2012). Predominant prevalence of arterial thrombosis in Japanese patients with antiphospholipid syndrome. Lupus 21, 1506-1514.
Galli, M., Luciani, D., Bertolini, G., and Barbui, T. (2003). Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 101, 1827-1832.
Giron-Gonzalez, J.A., Garcia del Rio, E., Rodriguez, C., Rodriguez-Martorell, J., and Serrano, A. (2004). Antiphospholipid syndrome and asymptomatic carriers of antiphospholipid antibody: prospective analysis of 404 individuals. J. Rheumatol. 31, 1560-1567.
Harris, E.N., Gharavi, A.E., Patel, B.M., and Hughes, G.R.V. (1987). Evaluation of the anti- cardiolipin antibody test: report of an international workshop held 4 April 1986. Clin. Exp. Immunol. 68, 215-222.
Hisada, R., Kato, M., Sugawara, E., Kanda, M., Fujieda, Y., Oku, K., Bohgaki, T., Amengual, O., Horita, T., Yasuda, S., et al. (2019). Circulating plasmablasts contribute to antiphospholipid antibody production, associated with type I interferon upregulation. J. Thromb. Haemost. 17, 1134-1143.
Hochberg, M.C. (1997). Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 40, 1725.
Hokusai, V.T.E.I., Buller, H.R., Decousus, H., Grosso, M.A., Mercuri, M., Middeldorp, S., Prins, M.H., Raskob, G.E., Schellong, S.M., Schwocho, L., et al. (2013). Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N. Engl. J. Med. 369, 1406-1415.
Investigators, E.-P., Buller, H.R., Prins, M.H., Lensin, A.W., Decousus, H., Jacobson, B.F., Minar, E., Chlumsky, J., Verhamme, P., Wells, P., et al. (2012). Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N. Engl. J. Med. 366, 1287-1297.
Investigators, E., Bauersachs, R., Berkowitz, S.D., Brenner, B., Buller, H.R., Decousus, H., Gallus, A.S., Lensing, A.W., Misselwitz, F., Prins, M.H., et al. (2010). Oral rivaroxaban for symptomatic venous thromboembolism. N. Engl. J. Med. 363, 2499-2510.
Jacobi, A.M., Mei, H., Hoyer, B.F., Mumtaz, I.M., Thiele, K., Radbruch, A., Burmester, G.R., Hiepe, F., and Dorner, T. (2010). HLA-DRhigh/CD27high plasmablasts indicate active disease in patients with systemic lupus erythematosus. Ann. Rheum. Dis. 69, 305-308.
Jones, R.B., Tervaert, J.W., Hauser, T., Luqmani, R., Morgan, M.D., Peh, C.A., Savage, C.O., Segelmark, M., Tesar, V., van Paassen, P., et al. (2010). Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N. Engl. J. Med. 363, 211-220.
Keeling, D., Mackie, I., Moore, G.W., Greer, I.A., Greaves, M., and British Committee for Standards in, H. (2012). Guidelines on the investigation and management of antiphospholipid syndrome. Br. J. Haematol. 157, 47-58.
Kelchtermans, H., Pelkmans, L., de Laat, B., and Devreese, K.M. (2016). IgG/IgM antiphospholipid antibodies present in the classification criteria for the antiphospholipid syndrome: a critical review of their association with thrombosis. J. Thromb. Haemost. 14, 1530- 1548.
Khamashta, M.A., Cuadrado, M.J., Mujic, F., Taub, N.A., Hunt, B.J., and Hughes, G.R. (1995). The management of thrombosis in the antiphospholipid-antibody syndrome. N. Engl. J. Med. 332, 993-997.
Lim, W., Crowther, M.A., and Eikelboom, J.W. (2006). Management of antiphospholipid antibody syndrome: a systematic review. JAMA. 295, 1050-1057.
Miyakis, S., Lockshin, M.D., Atsumi, T., Branch, D.W., Brey, R.L., Cervera, R., Derksen, R.H., PG, D.E.G., Koike, T., Meroni, P.L., et al. (2006). International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J. Thromb. Haemost. 4, 295-306.
Nakamura, M., Nishikawa, M., Komuro, I., Kitajima, I., Uetsuka, Y., Yamagami, T., Minamiguchi, H., Yoshimatsu, R., Tanabe, K., Matsuoka, N., et al. (2015a). Apixaban for the Treatment of Japanese Subjects With Acute Venous Thromboembolism (AMPLIFY-J Study). Circ. J. 79, 1230-1236.
Nakamura, M., Wang, Y.Q., Wang, C., Oh, D., Yin, W.H., Kimura, T., Miyazaki, K., Abe, K., Mercuri, M., Lee, L.H., et al. (2015b). Efficacy and safety of edoxaban for treatment of venous thromboembolism: a subanalysis of East Asian patients in the Hokusai-VTE trial. J. Thromb. Haemost. 13, 1606-1614.
Ohl, K., and Tenbrock, K. (2015). Regulatory T cells in systemic lupus erythematosus. Eur. J. Immunol. 45, 344-355.
Ohnishi, N., Fujieda, Y., Hisada, R., Nakamura, H., Kato, M., Oku, K., Bohgaki, T., Amengual, O., Yasuda, S., and Atsumi, T. (2019). Efficacy of dual antiplatelet therapy for preventing recurrence of arterial thrombosis in patients with antiphospholipid syndrome. Rheumatology (Oxford) 58, 969-974.
Otomo, K., Atsumi, T., Amengual, O., Fujieda, Y., Kato, M., Oku, K., Horita, T., Yasuda, S., and Koike, T. (2012). Efficacy of the antiphospholipid score for the diagnosis of antiphospholipid syndrome and its predictive value for thrombotic events. Arthritis Rheum. 64, 504-512.
Pengo, V., Biasiolo, A., Gresele, P., Marongiu, F., Erba, N., Veschi, F., Ghirarduzzi, A., de Candia, E., Montaruli, B., Testa, S., et al. (2007). Survey of lupus anticoagulant diagnosis by central evaluation of positive plasma samples. J. Thromb. Haemost. 5, 925-930.
Pengo, V., Biasiolo, A., Pegoraro, C., Cucchini, U., Noventa, F., and Iliceto, S. (2005). Antibody profiles for the diagnosis of antiphospholipid syndrome. Thromb. Haemost. 93, 1147-1152
Pengo, V., Denas, G., Zoppellaro, G., Jose, S.P., Hoxha, A., Ruffatti, A., Andreoli, L., Tincani, A., Cenci, C., Prisco, D., et al. (2018). Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood 132, 1365-1371.
Petzold, T., Thienel, M., Konrad, I., Schubert, I., Regenauer, R., Hoppe, B., Lorenz, M., Eckart, A., Chandraratne, S., Lennerz, C., et al. (2016). Oral thrombin inhibitor aggravates platelet adhesion and aggregation during arterial thrombosis. Sci. Transl. Med. 8, 367ra168.
Pierangeli, S.S., and Erkan, D. (2010). Antiphospholipid syndrome treatment beyond anticoagulation: are we there yet? Lupus 19, 475-485.
Radin, M., Cecchi, I., and Perez-Sanchez, C. (2017). Antiphospholipid antibodies negativization: time for testing for non-criteria aPL? Lupus 26, 1457-1458.
Rodriguez-Bayona, B., Ramos-Amaya, A., Perez-Venegas, J.J., Rodriguez, C., and Brieva, J.A. (2010). Decreased frequency and activated phenotype of blood CD27 IgD IgM B lymphocytes is a permanent abnormality in systemic lupus erythematosus patients. Arthritis Res. Ther. 12, R108.
Ruffatti, A., Del Ross, T., Ciprian, M., Nuzzo, M., Rampudda, M., Bertero, M.T., Bergia, R., Caramaschi, P., Biasi, D., Capsoni, F., et al. (2009). Risk factors for a first thrombotic event in antiphospholipid antibody carriers. A multicentre, retrospective follow-up study. Ann. Rheum. Dis. 68, 397-399.
Ruiz-Irastorza, G., Egurbide, M.V., Ugalde, J., and Aguirre, C. (2004). High impact of antiphospholipid syndrome on irreversible organ damage and survival of patients with systemic lupus erythematosus. Arch. Intern. Med. 164, 77-82.
Sciascia, S., Murru, V., Sanna, G., Roccatello, D., Khamashta, M.A., and Bertolaccini, M.L. (2012). Clinical accuracy for diagnosis of antiphospholipid syndrome in systemic lupus erythematosus: evaluation of 23 possible combinations of antiphospholipid antibody specificities. J. Thromb. Haemost. 10, 2512-2518.
Talaat, R.M., Mohamed, S.F., Bassyouni, I.H., and Raouf, A.A. (2015). Th1/Th2/Th17/Treg cytokine imbalance in systemic lupus erythematosus (SLE) patients: Correlation with disease activity. Cytokine 72, 146-153.
Tektonidou, M.G., Andreoli, L., Limper, M., Amoura, Z., Cervera, R., Costedoat-Chalumeau, N., Cuadrado, M.J., Dorner, T., Ferrer-Oliveras, R., Hambly, K., et al. (2019). EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann. Rheum. Dis. 78, 1296-1304.
Tektonidou, M.G., Laskari, K., Panagiotakos, D.B., and Moutsopoulos, H.M. (2009). Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies. Arthritis Rheum. 61, 29-36.
Yamada, N., Hirayama, A., Maeda, H., Sakagami, S., Shikata, H., Prins, M.H., Lensing, A.W., Kato, M., Onuma, J., Miyamoto, Y., et al. (2015). Oral rivaroxaban for Japanese patients with symptomatic venous thromboembolism - the J-EINSTEIN DVT and PE program. Thromb. J. 13, 2.
Zuily, S., de Laat, B., Mohamed, S., Kelchtermans, H., Shums, Z., Albesa, R., Norman, G.L., Lamboux-Matthieu, C., Rat, A.C., Ninet, J., et al. (2015). Validity of the global anti- phospholipid syndrome score to predict thrombosis: a prospective multicentre cohort study. Rheumatology (Oxford) 54, 2071-2075.
家子正裕, 高橋伸彦. (2013). 新規経口抗凝固療法における出血と虚血のリスク評価は可能か？ 心電図 33, 49-58.
論文の公開元へ
